It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Oligodendrocyte (OL) injury and subsequent loss is a pathologic hallmark of multiple sclerosis (MS). Stress granules (SGs) are membrane-less organelles containing mRNAs stalled in translation and considered as participants of the cellular response to stress. Here we show SGs in OLs in active and inactive areas of MS lesions as well as in normal-appearing white matter. In cultures of primary human adult brain derived OLs, metabolic stress conditions induce transient SG formation in these cells. Combining pro-inflammatory cytokines, which alone do not induce SG formation, with metabolic stress results in persistence of SGs. Unlike sodium arsenite, metabolic stress induced SG formation is not blocked by the integrated stress response inhibitor. Glycolytic inhibition also induces persistent SGs indicating the dependence of SG formation and disassembly on the energetic glycolytic properties of human OLs. We conclude that SG persistence in OLs in MS reflects their response to a combination of metabolic stress and pro-inflammatory conditions.
Oligodendrocyte (OL) injury and loss is a pathologic hallmark of multiple sclerosis. Here, the authors show the presence of stress granules in OLs in multiple sclerosis lesions, and their in vitro studies in human OLs indicate that stress granules formation is a response to a combination of metabolic stress and pro-inflammatory conditions.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 McGill University, Neuroimmunology Unit, Montreal Neurological Institute, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649)
2 McGill University Health Centre, Department of Neurosurgery, Montreal, Canada (GRID:grid.63984.30) (ISNI:0000 0000 9064 4811)
3 Montreal Children’s Hospital, Division of Pediatric Neurology, Montreal, Canada (GRID:grid.416084.f) (ISNI:0000 0001 0350 814X)
4 Montreal Children’s Hospital, Department of Pediatric Neurosurgery, Montreal, Canada (GRID:grid.416084.f) (ISNI:0000 0001 0350 814X)
5 Centre de Recherche Hospitalier de l’Université de Montréal, Montréal, Canada (GRID:grid.14848.31) (ISNI:0000 0001 2292 3357)
6 University of Saskatchewan, Cameco Multiple Sclerosis Neuroscience Research Center, Saskatoon, Canada (GRID:grid.25152.31) (ISNI:0000 0001 2154 235X)